- Takeda Pharmaceutical Co Ltd could start a clinical trial as early as July for a potential treatment of COVID-19 that is based on antibodies from recovered patients’ blood, company executives said on Wednesday.
“When the product will be available beyond the clinical study is still a bit unclear,” Kim said on an investor call. “But we do expect that before the end of the year, we should see some information in terms of broader use.” There are not yet any treatments for COVID-19, the disease caused by the coronavirus, which have been approved by the U.S. Food and Drug Administration. However, some such as Gilead Sciences Inc’s antiviral drug remdesivir have received emergency authorization from the regulator.
Start July 2021
Are these the same people with the faulty airbags that shot people full of shrapnel? If not maybe you should consider a name change. 'Takeda... Not that one'